Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468425 | 0.87 | MAPT (0.74) | ADRB1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8318825 | 0.84 | MAPT (0.59) | HTR3AKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24140572 | 0.83 | ADRB1 (0.68) | ADRB1KDM4ESMN1; SMN2GAAMAPT | |
| SCHEMBL3539353 | 0.83 | ADRB1 (0.68) | ADRB1KDM4ESMN1; SMN2GAAMAPT | |
| SCHEMBL14924457 | 0.82 | KDM4E (0.51) | ADRB1HTR3AKDM4ENPC1RAB9A | |
| SCHEMBL21761804 | 0.82 | KDM4E (0.51) | ADRB1HTR3AKDM4ENPC1RAB9A | |
| SCHEMBL6150891 | 0.82 | GAA (0.69) | ADRB1HTR3AKDM4ENPC1RAB9A | |
| SCHEMBL6151809 | 0.82 | GAA (0.69) | ADRB1HTR3AKDM4ENPC1RAB9A | |
| SCHEMBL1527203 | 0.82 | GAA (0.64) | ADRB1HTR3AKDM4ENPC1RAB9A | |
| SCHEMBL14922269 | 0.82 | KMT2A (0.53) | HTR3AKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024039210-A1 | COMPOUNDS FOR INHIBITING OR DECOMPOSING CDK2 AND/OR CDK9, AND MEDICINAL USES THEREOF | 한국화학연구원 | 2024-02-22 | — | — | WO | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| EP-3971182-A1 | 2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3541814-B1 | 2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC THERAPEUTICS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210061768-A1 | 2-SUBSTITUTED AMINO-NAPHTH (1,2-D) IMIDAZOL-5-ONE COMPOUNDS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-1966191-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-17 | — | — | EP | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| US-5945421-A | TREATING PSYCHOSIS AND SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | ADRB1 15/4885HTR3A 91/4885KDM4E 3069/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | ADRB1 2672/4885HTR3A 4126/4885KDM4E 305/4885 |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ADRA2C, ADRB2, ADRA2A | ADRB1 9/4885HTR3A 74/4885KDM4E 3808/4885 |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | DPYD, TYMP, TYMS | ADRB1 3177/4885HTR3A 670/4885KDM4E 1501/4885 |
| US-20210061768-A1 | 2-SUBSTITUTED AMINO-NAPHTH (1,2-D) IMIDAZOL-5-ONE COMPOUNDS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLS2, GOT2, SMN1; SMN2 | ADRB1 1550/4885HTR3A 1570/4885KDM4E 4452/4885 |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | HTR6, HTR5A, HTR7 | ADRB1 99/4885HTR3A 10/4885KDM4E 2908/4885 |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | ADRB1 2672/4885HTR3A 4126/4885KDM4E 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.